Logo do repositório
 
Publicação

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis

2025-08Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorTorres, Tiago
dc.contributor.authorYeung, Jensen
dc.contributor.authorPrajapati, Vimal H.
dc.contributor.authorRibero, Simone
dc.contributor.authorBalato, Anna
dc.contributor.authorMarzano, Angelo Valerio
dc.contributor.authorCruz, Maria João
dc.contributor.authorPaiva Lopes, Maria João
dc.contributor.authorPaiva-Lopes, Maria
dc.contributor.authorLazaridou, Elizabeth
dc.contributor.authorCarrascosa, Jose Manuel
dc.contributor.authorAlvarenga, José Miguel
dc.contributor.authorFarinha, Pedro
dc.contributor.authorFarinha, Pedro
dc.contributor.authorDuarte, Bruno
dc.contributor.authorMunera-Campos, Monica
dc.contributor.authorSood, Siddhartha
dc.contributor.authorRankin, Brian D.
dc.contributor.authorOrtoncelli, Michela
dc.contributor.authorCaccavale, Stefano
dc.contributor.authorFerrucci, Silvia Mariel
dc.contributor.authorPires Rosa, Gilberto
dc.contributor.authorDaponte, Athina Ioanna
dc.contributor.authorSilvi, Gianmarco
dc.contributor.authorPeris, Ketty
dc.contributor.authorGori, Niccolò
dc.contributor.authorPrignano, Francesca
dc.contributor.authorKolios, Antonio
dc.contributor.authorHerranz, Pedro
dc.contributor.authorGregoriou, Stamatios
dc.contributor.authorRompoti, Natalia
dc.contributor.authorGkalpakiotis, Spyridon
dc.contributor.authorChiricozzi, Andrea
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblAdis
dc.date.accessioned2025-09-30T22:00:59Z
dc.date.available2025-09-30T22:00:59Z
dc.date.issued2025-08
dc.description.abstractIntroduction: Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial. In this international, multicenter, retrospective, comparative study we aimed to evaluate the 52-week effectiveness, safety, and tolerability of dupilumab, tralokinumab, and upadacitinib in patients with AD aged ≥ 12 years. Methods: Effectiveness was assessed at weeks 16, 24, and 52 using Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (NRS) scores. Safety was measured via adverse events (AEs). Results: A total of 1286 treatment courses were included: 62.5% received dupilumab, 24.3% received upadacitinib, and 13.1% received tralokinumab. Upadacitinib demonstrated higher effectiveness than dupilumab and tralokinumab across all time points and most evaluated outcomes both on the overall population and the biologic-/JAKi-naïve population, including stringent treatment targets such as EASI 90 response and combined EASI 90 + itch NRS 0/1 response. While upadacitinib demonstrated superior effectiveness, it was associated with a higher incidence of AEs, both leading to and not leading to treatment discontinuation, including thromboembolic events, lipid abnormalities, and hematologic abnormalities. In contrast, conjunctivitis was the most frequently observed AE among patients receiving biologics. Conclusion: This study provides a comprehensive real-world comparison of dupilumab, tralokinumab, and upadacitinib in AD, highlighting upadacitinib’s superior effectiveness in achieving stringent treatment targets, both in the short and long term, but also a higher incidence of AEs. However, the considerable heterogeneity of the study population, an inherent limitation of real-world studies, must be acknowledged when interpreting these findings.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent485265
dc.identifier.doi10.1007/s13555-025-01453-8
dc.identifier.issn2193-8210
dc.identifier.otherPURE: 118212785
dc.identifier.otherPURE UUID: e771df13-aab6-493d-8a4c-2dc30f65a8cb
dc.identifier.otherScopus: 105007069907
dc.identifier.otherWOS: 001501523900001
dc.identifier.urihttp://hdl.handle.net/10362/188803
dc.identifier.urlhttps://www.scopus.com/pages/publications/105007069907
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAtopic dermatitis
dc.subjectDupilumab
dc.subjectEffectiveness
dc.subjectSafety
dc.subjectTralokinumab
dc.subjectUpadacitinib
dc.subjectDermatology
dc.titleReal-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitisen
dc.title.subtitleA 52-Week International, Multicenter Retrospective Cohort Studyen
dc.typejournal article
degois.publication.firstPage2295
degois.publication.issue8
degois.publication.lastPage2305
degois.publication.titleDermatology and Therapy
degois.publication.volume15
dspace.entity.typePublication
person.familyNamePaiva-Lopes
person.familyNameFarinha
person.givenNameMaria
person.givenNamePedro
person.identifier2389900
person.identifier.ciencia-idAA13-C4F0-44C6
person.identifier.orcid0000-0001-9189-2734
person.identifier.orcid0000-0001-9364-9391
person.identifier.scopus-author-id13606257800
person.identifier.scopus-author-id6602222404
rcaap.rightsopenAccess
relation.isAuthorOfPublication850d84d5-815b-4d3e-922a-6358b2f551c1
relation.isAuthorOfPublicationaa160faf-56d5-4c0f-9aed-bae18c5efd84
relation.isAuthorOfPublication.latestForDiscovery850d84d5-815b-4d3e-922a-6358b2f551c1

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
s13555-025-01453-8.pdf
Tamanho:
473.89 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica